A Comprehensive Evaluation of Sdox, a Promising H2S-Releasing Doxorubicin for the Treatment of Chemoresistant Tumors

• Main Authors: Petko Alov (Author), Merilin Al Sharif (Author), Denitsa Aluani (Author), Konstantin Chegaev (Author), Jelena Dinic (Author), Aleksandra Divac Rankov (Author), Miguel X. Fernandes (Author), Fabio Fusi (Author), Alfonso T. García-Sosa (Author), Risto Juvonen (Author), Magdalena Kondeva-Burdina (Author), José M. Padrón (Author), Ilza Pajeva (Author), Tania Pencheva (Author), Adrián Puerta (Author), Hannu Raunio (Author), Chiara Riganti (Author), Ivanka Tsakovska (Author), Virginia Tzankova (Author), Yordan Yordanov (Author), Simona Saponara (Author)
• Format: Book
• Published: Frontiers Media S.A., 2022-03-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Sdox is a hydrogen sulfide (H2S)-releasing doxorubicin effective in P-glycoprotein-overexpressing/doxorubicin-resistant tumor models and not cytotoxic, as the parental drug, in H9c2 cardiomyocytes. The aim of this study was the assessment of Sdox drug-like features and its absorption, distribution,...